Abstract 217P
Background
PTCH1, a tumor suppressor and inhibitor of the hedgehog pathway. Hh signaling was reported to modulate the tumor microenvironment by increasing immune checkpoint expression and promoting an inflammatory environment. Mutations of PTCH1 are potential therapeutic targets, Hh pathway inhibitor has been developed as a treatment for patients with advanced solid tumors. It is thus important to understand the genomic landscape of PTCH1 mutation. Here, we explored PTCH1 mutation profiles in Chinese solid tumors.
Methods
Next-generation sequencing of 551-gene profiling was performed to analyze postoperative tissues from 22312 Chinese solid tumors in 2019-2022. Somatic mutations and copy number variations were detected following the standard operating procedure.
Results
PTCH1 mutations were present in 3.1% of patients with advanced solid tumors, a total of 791 PTCH1 somatic mutations were detected in 684 tumor samples. The higher frequency cancer type contained lung cancer(n=239), colorectal cancer(n=137), and stomach cancer(n=60). Of 791 PTCH1 mutations, missense mutations(65%,n=514) were more observed, and 25% were loss of function (LOF) mutations, including frameshift(n=124), nonsense(n=50), splicing(n=23) mutations. Exon 23, exon1 and exon22 of PTCH1 were the main mutational hotspot regions found, with p.S1203Afs*52 (n=26), p.R1308Efs*64 (n=22), p.R602* (n=11), p.Y1316Tfs*56 (n=11) being the most frequent mutations in our study. There was a significant statistical difference in TMB values that the PTCH1 mutant group was higher than the PTCH1 wild-type group (39 vs. 5, p < 0.001), and patients who presented with two or more PTCH1 mutations with higher compared with those patients carried only a single mutation (129 vs. 29, p < 0.001). TMB in PTCH1 frameshift_variant tumors (53, 0–672) was significantly higher than TMB in PTCH1 splice variant tumors (15, 0–60; P < 0.05). The proportion of PTCH1 alterations in MSI-H tumors was higher than those without mutations (22% vs. 1%, p < 0.001).
Conclusions
In our study, PTCH1 mutations are present in 3.1% of solid tumors, and mostly occurred in exon 23, exon1, and exon22. PTCH1 mutant tumors tended to be associated with higher TMB values (39 vs. 5), therefore, Hh pathway inhibitor combined immunotherapy may be considered in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
175P - Radiomic biomarker of vessel tortuosity for monitoring treatment change: Preliminary findings in prospective evaluation of ECOG-ACRIN EA5163
Presenter: Pushkar Mutha
Session: Poster session 01
176P - Enhancing immunotherapy response prediction via multimodal integration of radiology and pathology deep learning models
Presenter: Marta Ligero
Session: Poster session 01
177P - Revealing differences in radiosensitivity of advanced non-small cell lung cancer (NSCLC)through single-cell sequencing data
Presenter: Peimeng You
Session: Poster session 01
178P - Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients
Presenter: Leonardo Provenzano
Session: Poster session 01
179P - Molecular tumor board directed treatment for patients with advanced stage solid tumors: A case-control study
Presenter: Dhruv Bansal
Session: Poster session 01
180P - An HLA-diet-oriented system unveiling organ-specific occurrence of multiple primary cancers (MPC) with prevention strategy: A large cohort study of 47,550 cancer patients
Presenter: Zixuan Rong
Session: Poster session 01
181P - GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative
Presenter: Philippe Aftimos
Session: Poster session 01
182P - ALK fusion detection by RNA next-generation sequencing (NGS) compared to DNA in a large, real-world non-small cell lung cancer (NSCLC) dataset
Presenter: Wade Iams
Session: Poster session 01
183P - Frequency of actionable fusions in 7,735 patients with solid tumors
Presenter: Kevin McDonnell
Session: Poster session 01
184P - Patient-specific HLA-I genotypes predict response to immune checkpoint blockade
Presenter: Kyrillus Shohdy
Session: Poster session 01